PLEASE REVIEW THE FOLLOWING INFORMATION AND CLICK "ENTER ACTIVITY" TO CONTINUE
Metabolic Fate of Pharmaceuticals: Focus on Slow Metabolizers

Genetic polymorphism of drug metabolism is a clinically relevant issue that has been associated with serious clinical consequences, as supported by scientific literature. A subpopulation of individuals who receive second- and third-generation antihistamines are identified as poor metabolizers, and this program is intended for allergists and primary care physicians to raise awareness of the potential issues associated with genetic polymorphism in drug metabolism. You are invited to particapate in a continuing medical education (CME) slide lecture presentation examining the clinical impact of antihistamines in slow metabolizers.This activity consists of a review of slides and accompanying annotations; the subsequent post-test and evaluation must be completed and submitted in order to earn CME credit.

Learning Objectives

	Define genetic polymorphism of drug metabolism, recognize the poor metabolizer phenotype, and describe prevalence of these poor metabolizers in the general population
	Identify known polymorphisms of drug metabolism, including slow hydroxylation and slow N-acetylation
	Discuss clinical consequences associated with altered drug metabolism in the poor metabolizer population
	Evaluate individuals with genetic polymorhism and improve understanding of interpatient variability in drug metabolism and clinical response

	Sponsored by Quintiles Medical Communications Hawthorne, NY
	Supported by An unrestricted educational grant from Aventis Pharmaceuticals